University of Worcester Worcester Research and Publications
 
  USER PANEL:
  ABOUT THE COLLECTION:
  CONTACT DETAILS:

Pharmaconutrition in the clinical management of COVID-19: a lack of evidence-based research but clues to personalized prescription

Santos, H.O., da Silva, G., Tinsley, G. and Bueno, Allain ORCID: https://orcid.org/0000-0002-9456-8558 (2020) Pharmaconutrition in the clinical management of COVID-19: a lack of evidence-based research but clues to personalized prescription. Journal of Personalized Medicine, 10. Article no. 145. ISSN 2075-4426

[thumbnail of Version of Record]
Preview
Text (Version of Record)
Bueno-2020-VoR-Pharmaconutrition-in-the-clinical-management-of-COVID-19.pdf - Published Version
Available under License Creative Commons Attribution.

Download (742kB) | Preview

Abstract

A scientific interest has emerged to identify pharmaceutical and nutritional strategies in the
clinical management of coronavirus disease 2019 (COVID-19). The purpose of this narrative review is to critically assess and discuss pharmaconutrition strategies that, secondary to accepted treatment methods, could be candidates in the current context of COVID-19. Oral medicinal doses of vitamin C (1–3 g/d) and zinc (80 mg/d elemental zinc) could be promising at the first signs and symptoms of COVID-19 as well as for general colds. In critical care situations requiring parenteral nutrition, vitamin C (3–10 g/d) and glutamine (0.3–0.5 g/kg/d) administration could be considered, whereas vitamin D3 administration (100,000 IU administered intramuscularly as a one-time dose) could possess benefits for patients with severe deficiency. Considering the presence of n-3 polyunsaturated fatty acids and arginine in immune-enhancing diets, their co-administration may also occur in clinical conditions where these formulations are recommended. However, despite the use of the aforementioned strategies in prior contexts, there is currently no evidence of the utility of any nutritional strategies in the management of SARS-CoV-2 infection and COVID-19. Nevertheless, ongoing and future clinical research is imperative to determine if any pharmaconutrition strategies can halt the progression
of COVID-19.

Item Type: Article
Additional Information:

The full-text of the online published article can be accessed via the official URL.

© The authors. This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Uncontrolled Discrete Keywords: severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, coronavirus disease 2019, COVID-19, nutrition, supplementation
Subjects: Q Science > Q Science (General)
R Medicine > R Medicine (General)
Divisions: College of Health, Life and Environmental Sciences > School of Science and the Environment
Related URLs:
Copyright Info: Open access article
Depositing User: Allain Bueno
Date Deposited: 27 Aug 2020 12:05
Last Modified: 07 Dec 2020 17:13
URI: https://worc-9.eprints-hosting.org/id/eprint/9663

Actions (login required)

View Item View Item
 
     
Worcester Research and Publications is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.